{
  "meta": {
    "data_length": 1,
    "message": "Indication id ind:ema:rybrevant:2 retrieved successfully",
    "request_url": "http://api.moalmanac.org/indications?indication_id=ind%3Aema%3Arybrevant%3A2",
    "status": "success",
    "status_code": 200,
    "timestamp_elapsed": 0.008806,
    "timestamp_received": "2026-09-25T06:01:46.721298+00:00Z",
    "timestamp_returned": "2026-09-25T06:01:46.730104+00:00Z",
    "trace_id": "404dbf97-2f9a-4b20-81ab-d65c35d9f6e9"
  },
  "service": {
    "github": "https://github.com/vanallenlab/moalmanac-db",
    "name": "Molecular Oncology Almanac",
    "license": "GPL-2.0",
    "release": "draft",
    "url": "https://dev.moalmanac.org",
    "last_updated": "2026-08-02"
  },
  "data": [
    {
      "id": "ind:ema:rybrevant:2",
      "type": "Indication",
      "description": "Rybrevant is indicated in combination with carboplatin and pemetrexed for the treatment of adult patients with advanced NSCLC with EGFR Exon 19 deletions or Exon 21 L858R substitution mutations after failure of prior therapy including an EGFR tyrosine kinase inhibitor (TKI).",
      "contributions": [
        {
          "id": "ctrb:vanallenlab:2025-09-05:0",
          "type": "Contribution",
          "description": "On 2025-03-11, the EMA published an EPAR - Assessment report - Variation for Rybrevant (amivantamab)that added an extension indication to amivantamab in combination with carboplatin and pemetrexed for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with EGFR Exon 19 deletions or Exon 21 L858R substitution mutations after failure of prior therapy including an EGFR tyrosine kinase inhibitor (TKI).",
          "date": "2025-09-05",
          "contributor": {
            "id": "agent:user:vanallenlab",
            "type": "Agent",
            "agentType": "contributor",
            "name": "Van Allen lab",
            "description": "Van Allen lab, Dana-Farber Cancer Institute"
          }
        },
        {
          "id": "ctrb:ema:2024-08-22:0",
          "type": "Contribution",
          "description": "Indication received approval from the European Commission.",
          "date": "2024-08-22",
          "contributor": {
            "id": "agent:org:ema",
            "type": "Agent",
            "agentType": "organization",
            "name": "European Medicines Agency",
            "description": "Regulatory agency that approves medicines for use in the European Union."
          }
        }
      ],
      "reportedIn": [
        {
          "id": "doc:ema:rybrevant",
          "type": "Document",
          "documentType": "Regulatory approval",
          "name": "Rybrevant (amivantamab) [product information]. EMA.",
          "title": null,
          "aliases": [],
          "description": "Janssen-Cilag International N.V. Rybrevant (amivantamab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/rybrevant-epar-product-information_en.pdf. Revised July 2025. Accessed September 5, 2025.",
          "urls": [
            "https://www.ema.europa.eu/en/documents/product-information/rybrevant-epar-product-information_en.pdf",
            "https://www.ema.europa.eu/en/medicines/human/EPAR/rybrevant"
          ],
          "doi": null,
          "pmid": null,
          "extensions": [
            {
              "name": "agent",
              "value": {
                "id": "agent:org:ema",
                "type": "Agent",
                "agentType": "organization",
                "name": "European Medicines Agency",
                "description": "Regulatory agency that approves medicines for use in the European Union."
              },
              "description": "The organization that published this document."
            },
            {
              "name": "company",
              "value": "Janssen-Cilag International N.V.",
              "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents."
            },
            {
              "name": "drug_name_brand",
              "value": "Rybrevant",
              "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents."
            },
            {
              "name": "drug_name_generic",
              "value": "amivantamab",
              "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents."
            },
            {
              "name": "first_publication_date",
              "value": "2022-02-01",
              "description": "The publication date for the initial version of this document."
            },
            {
              "name": "identification_number",
              "value": null,
              "description": "Identification number used by the publishing organization."
            },
            {
              "name": "publication_date",
              "value": "2025-07-18",
              "description": "The publication date for the document."
            },
            {
              "name": "status",
              "value": "Active",
              "description": "Whether this document is Active or Deprecated within moalmanac-db."
            }
          ]
        }
      ],
      "extensions": [
        {
          "name": "status",
          "value": "Approved",
          "description": "Current approval status."
        }
      ]
    }
  ]
}